Table 1.
Major pharmacokinetic parameters of administered ABD-GCSF in a neutropenic rat model.
| Proteins | Tmax (h) | Cmax (ng/ml) | AUC (0-t) (ng h/ml) | AUC (0-∞) (ng h/ml) | Ka (h−1) | Ke (h−1) | t1/2 (h) | CL/F (ml/h/kg) | MRT (h) |
|---|---|---|---|---|---|---|---|---|---|
| Filgrastim | 2.0 ± 0.0 | 552.3 ± 47.7 | 2406.6 ± 218.0 | 2315.3 ± 129.3 | 1.22 ± 0.11 | 0.4 ± 0.00 | 1.7 ± 0.1 | 43.3 ± 2.3 | 3.4 ± 0.1 |
| PEG-Filgrastim | 24.0 ± 0.0* | 481.7 ± 45.2* | 16,773.8 ± 2371.8* | 16,773.8 ± 2371.8* | 0.103 ± 0.001 | 0.07 ± 0.00* | 10.0 ± 0.5* | 6.056 ± 0.83* | 17.9 ± 2.2* |
| ABD-GCSF | 10.0 ± 0.0* | 353 ± 32.0* | 6038 ± 520.7* | 6232.1 ± 531.5* | 0.187 ± 0.004 | 0.08 ± 0.0* | 9.3 ± 0.7* | 16.1 ± 1.4* | 9.9 ± 0.4* |
Data is represented as the means ± SD of 5 rats/group.
Tmax, Time to reach the peak plasma concentration; t1/2, Elimination half-life; Cmax, Maximum observed plasma concentration; Ke, Elimination rate constant; CL/F, Apparent total clearance; AUC, Area under the serum concentration–time curve; MRT Mean residence time.
*P < 0.05 in comparison with the Filgrastim group.